Medtronic’s DES Program Sails Full Speed Ahead; Analysts Spy Iceberg
This article was originally published in The Gray Sheet
Executive Summary
The strength of Medtronic's drug-eluting stent pipeline renders acquisitions or partnerships unnecessary, the company asserts, citing confidence in U.S. commercialization of Endeavor by early 2006